Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New appointment at NormOxys

This article was originally published in Scrip

Executive Summary

NormOxys, a US biotechnology company developing a class of small-molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, has appointed Dr Martin Tolar president and chief executive officer. Dr Tolar was most recently chief scientific officer and later executive vice-president and chief business officer at CoMentis. NormOxys has also leased a 3,500ft2 space in Wellesley, Massachusetts, to serve as its new corporate headquarters.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC005905

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel